Novo reports positive Phase III REDEFINE 1 results for CagriSema
Novo Nordisk reported post hoc results from the Phase III REDEFINE 1 trial of CagriSema, showing 67.8% of participants achieved early responder status with 25.4% mean weight reduction at 68 weeks. Safety data indicated higher discontinuation and gastrointestinal effects for CagriSema vs. placebo. The company submitted an NDA for CagriSema in December 2025, with a decision expected in Q4 2026.
How this was made
The 30-second read
Why it matters
The disclosed efficacy (67.8% early responders, up to 25.4% weight loss) and safety profile (5.9% discontinuations) provide the first detailed efficacy read‑out, likely influencing the upcoming FDA decision and market perception.
Market read
Positive Phase III data could lift Novo Nordisk shares ahead of the FDA decision, while also raising expectations for the broader obesity‑treatment market.
What to watch
The trial was post‑hoc; regulatory reviewers may request additional prospective data, which could delay approval.
Background
Novo Nordisk is a leading diabetes and obesity drugmaker. CagriSema combines cagrilintide (amylin analogue) with semaglutide (GLP‑1RA). The company filed an NDA in Dec 2025 with FDA decision expected Q4 2026.
Ticker impact
Novo Nordisk disclosed post‑hoc Phase III REDEFINE 1 results showing strong early‑responder weight loss for its CagriSema combo therapy.
likely upward pressure as market prices in the favorable efficacy data
First public disclosure of detailed efficacy and safety outcomes; Novo has an NDA pending, making the news material for the stock.
Market effects
obesity/weight‑loss therapeutics sector may see increased investor interest and higher valuations for peers.
European and US biotech markets could experience modest gains on the back of positive obesity drug data.
global obesity treatment market outlook improves, but impact remains limited to pharma equities.
Counterpoint
Investors may question the high gastrointestinal adverse‑event rate and the need for further confirmatory data before the NDA decision.
Key entities
- companyNovo Nordisk
US‑listed pharmaceutical company (ticker NVO) developing obesity treatments.
- drugCagriSema
Investigational combination therapy of cagrilintide and semaglutide.


